INS and type 2 diabetes mellitus: In fact, these ‘metabolic amplification’ pathways may act early to set the amplitude of glucose‐induced secretory responses – and reduced efficacy of this pathway may contribute to impaired insulin secretion in type 2 diabetes (T2D) (Grespan et al., 2018).